Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Purchases $109,100.00 in Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Michael Harrington bought 5,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the completion of the transaction, the director owned 131,451 shares in the company, valued at approximately $2,868,260.82. This trade represents a 3.95% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Elanco Animal Health Trading Up 1.8%

Shares of NYSE ELAN traded up $0.39 during mid-day trading on Thursday, hitting $22.52. The company’s stock had a trading volume of 5,574,051 shares, compared to its average volume of 5,740,837. The stock has a market cap of $11.25 billion, a price-to-earnings ratio of -54.93, a price-to-earnings-growth ratio of 1.36 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The company’s fifty day simple moving average is $24.60 and its 200-day simple moving average is $24.04.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.27 by $0.07. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. Elanco Animal Health’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Morgan Stanley raised their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 22nd. Weiss Ratings raised Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, July 31st. Citigroup upped their price objective on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, KeyCorp increased their target price on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently bought and sold shares of the company. NewEdge Advisors LLC boosted its position in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Elanco Animal Health in the 2nd quarter valued at $38,000. Root Financial Partners LLC increased its position in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in Elanco Animal Health during the 4th quarter worth $41,000. Finally, Torren Management LLC bought a new position in Elanco Animal Health during the fourth quarter worth about $46,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.